Holen Sie sich die Stockscreener-App
1.44
1.01%
-0.04
Schlusskurs vom Vortag:
$1.48
Offen:
$1.5
24-Stunden-Volumen:
73,100
Relative Volume:
0.25
Marktkapitalisierung:
$173.10M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-13.73M
KGV:
-11.08
EPS:
-0.13
Netto-Cashflow:
$-3.92M
1W Leistung:
-8.44%
1M Leistung:
-15.32%
6M Leistung:
-2.98%
1J Leistung:
+99.05%
1-Tages-Spanne:
$1.44
$1.52
1-Wochen-Bereich:
$1.44
$1.61
52-Wochen-Spanne:
$0.6302
$2.60
Tiziana Life Sciences Ltd Stock (TLSA) Company Profile
Firmenname
Tiziana Life Sciences Ltd
Sektor
Branche
Telefon
-
Adresse
-
Vergleichen Sie TLSA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TLSA
Tiziana Life Sciences Ltd
|
1.44 | 177.91M | 0 | -13.73M | -3.92M | -0.13 |
|
VRTX
Vertex Pharmaceuticals Inc
|
472.17 | 119.17B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
811.91 | 84.19B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
408.64 | 52.77B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
815.66 | 48.98B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.96 | 36.31B | 447.02M | -1.18B | -906.14M | -6.1812 |
Tiziana Life Sciences Ltd Stock (TLSA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2020-12-22 | Eingeleitet | B. Riley Securities | Buy |
| 2018-12-17 | Eingeleitet | Laidlaw | Buy |
Tiziana Life Sciences Ltd Aktie (TLSA) Neueste Nachrichten
Tiziana Life Sciences to Showcase Intranasal Foralumab at Neuroscience Innovation Forum During JPM Week - TipRanks
Tiziana Life Sciences to Present at the 9th Annual Neuroscience Innovation Forum During J.P. Morgan Healthcare Conference Week in San Francisco - The Manila Times
Tiziana Life Sciences to present at 9th Annual Neurosciences Innovation Forum - Proactive financial news
Why Tiziana Life Sciences Ltd stock is rated strong buyQuarterly Portfolio Review & Safe Swing Trade Setup Alerts - ulpravda.ru
Tiziana Life Sciences (NASDAQ:TLSA) Trading Up 7.4% – Still a Buy? - Defense World
Tiziana Life Sciences (NASDAQ:TLSA) Trading Up 7.4%Still a Buy? - MarketBeat
Tiziana Life Sciences Files Annual Safety Report for Intranasal Foralumab with FDA - MarketScreener
Tiziana Life Sciences files annual safety report for intranasal foralumab - Yahoo Finance
Is Tiziana Life Sciences Ltd a good long term investmentSupport and Resistance Levels & Free Risk Assessment and Control - earlytimes.in
Tiziana Life Sciences submits annual safety report for intranasal foralumab to FDA - Proactive financial news
Tiziana Life Sciences Reports Positive Safety Profile for Intranasal Foralumab Following 37.4 Patient-Years of Exposure - Quiver Quantitative
Tiziana Files Annual Safety Report for Intranasal Foralumab with FDA - The Manila Times
Small cap wrap: Tiziana Life Sciences, 374Water, First Phosphate... - Proactive financial news
Operating expenses (excl. COGS) of Tiziana Life Sciences Ltd. – GETTEX:0RP - TradingView — Track All Markets
Tiziana Life Sciences begins dosing in Phase 2 Alzheimer’s trialICYMI - Proactive financial news
Tiziana Life Sciences Announces Acquisition of Shares by Executive Chairman - The Manila Times
Tiziana Life Sciences Chair Boosts Stake to 36% with December Share Purchase - TipRanks
How buybacks impact Tiziana Life Sciences Ltd stock valueRecession Risk & Reliable Breakout Stock Forecasts - Улправда
Tiziana Life Sciences chairman increases stake to over 36% By Investing.com - Investing.com South Africa
Tiziana Life Sciences (TLSA) Chairman Expands Stake in the Compa - GuruFocus
Tiziana Life Sciences executive chairman increases stake - Proactive financial news
Why Tiziana Life Sciences Ltd stock is considered a top pickWeekly Stock Summary & Daily Risk Controlled Trade Plans - Bölüm Sonu Canavarı
Tiziana Life Sciences Executive Chairman Gabriele Cerrone Acquires Additional Shares, Increasing Ownership to 36.08% - Quiver Quantitative
Tiziana Life Sciences chairman increases stake to over 36% - Investing.com
Biotech founder lifts personal stake to 36% with latest share buy - Stock Titan
Can Tiziana Life Sciences Ltd stock maintain operating marginsShort Setup & Free Weekly Chart Analysis and Trade Guides - Улправда
Is Tiziana Life Sciences Ltd stock a buy on dipsIPO Watch & Safe Entry Zone Tips - DonanımHaber
Is Tiziana Life Sciences Ltd stock gaining market share2025 Market Overview & Daily Volume Surge Signals - Улправда
What risks investors should watch in Tiziana Life Sciences Ltd stockJuly 2025 Setups & Free Low Drawdown Momentum Trade Ideas - Улправда
How Tiziana Life Sciences Ltd stock performs during Fed tightening cyclesJuly 2025 Intraday Action & Stepwise Swing Trade Plans - Улправда
Tiziana Life Sciences Rings the Nasdaq Stock Market Closing Bell - Nasdaq
Small cap wrap: Tiziana Life Sciences, NanoViricides, 1911 Gold, Protalix BioTherapeutics… - Proactive Investors
Tiziana Life Sciences doses first patient in Phase 2 Alzheimer’s clinical trial - Proactive financial news
Tiziana Life Sciences (NASDAQ: TLSA) marks Nasdaq bell with foralumab - Stock Titan
Tiziana Life Sciences to Ring the Closing Bell at Nasdaq - The Manila Times
Biotech behind nasal antibody for Alzheimer's to ring Nasdaq bell - Stock Titan
Tiziana Life Sciences doses first patient in Phase 2 Alzheimer's clinical trial - MarketScreener
TLSA Initiates Phase 2 Trial of Intranasal Foralumab for Alzheimer's Patients - GuruFocus
Tiziana Life Sciences Doses First Patient in Phase 2 Alzheimer’s Clinical Trial - The Manila Times
Tiziana Life Sciences doses first patient in mid-stage Alzheimer’s trial - Proactive Investors
Tiziana Life Sciences Doses First Patient with Intranasal Foralumab in Phase 2 Alzheimer’s Disease Trial - Quiver Quantitative
Tiziana Life Sciences (TLSA) begins Phase 2 intranasal foralumab AD trial - Stock Titan
New intranasal antibody trial targets neuroinflammation in early Alzheimer’s - Stock Titan
Tiziana Life Sciences Announces Purchase of Shares by Chief Executive Officer - The Manila Times
Tiziana Life Sciences CEO purchases 163,400 shares in open market By Investing.com - Investing.com Canada
Tiziana Life Sciences (TLSA) CEO boosts stake with 163,400-share purchase - Stock Titan
TLSA CEO Bolsters Stake with New Share Acquisition - GuruFocus
Tiziana Life Sciences CEO Increases Stake With Share Purchase - marketscreener.com
Tiziana Life Sciences CEO purchases 163,400 shares in open market - Investing.com
Ivor Elrifi Acquires Additional Shares of Tiziana Life Sciences Amidst Ongoing Clinical Development of Foralumab - Quiver Quantitative
Tiziana (NASDAQ: TLSA) CEO buys 163,400 shares in open market, now 357,848 - Stock Titan
Finanzdaten der Tiziana Life Sciences Ltd-Aktie (TLSA)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.59%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):